FDA Grants Breakthrough Status to Revolutionary Postpartum Depression Treatment Luvesilocin shows substantial improvement over existing options for new mothers The FDA has granted Breakthrough Therapy designation to luvesilocin for postpartum depression following encouraging results from Phase 2 clinical trials, potentially accelerating access to a desperately needed treatment for new mothers.